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Objective: The identification of sex-based disparities in the use of effective medications in high-risk populations
can lead to interventions to minimize disparities in health outcomes. The objective of this study was to determine
sex-specific rates of cardioprotective medication use in a large population-level administrative-health database from
a universal-payer environment.
Research design and methods: This observational, population-based cohort study used provincial administrative
data to compare the utilization of cardioprotective medications between women and men in the first year following a
diabetes diagnosis. Competing risks regression was used to calculate crude and adjusted sub-hazard ratios for time-to-
first angiotensin-converting-enzyme inhibitor, angiotensin receptor blocker, or statin dispensations.
Results: There were 15,120 (45.4%) women and 18,174 (54.6%) men with diabetes in the study cohort. Overall
cardioprotective medication use was low for both primary and secondary prevention for both women and men. In the
year following a diabetes diagnosis, women were less likely to use a statin relative to men (adjusted sub-hazard ratio
[aSHR] 0.90, 95% confidence interval [CI] 0.85 to 0.96), angiotensin-converting-enzyme inhibitors (aSHR 0.90, 95% CI 0.86
to 0.94), or any cardioprotective medication (aSHR 0.93, 95% CI 0.90 to 0.97).
Conclusions: Cardioprotective medication use was not optimal in women or men. We also identified a health care gap
with cardioprotective medication use being lower in women with diabetes compared to men. Closing this gap has the
potential to reduce the impact of cardiovascular disease in women with diabetes.Cardiovascular disease is the leading cause of death in
both women and men [1]. It is also the leading cause of
morbidity and mortality for those living with diabetes.
Compared to non-diabetic individuals, women and men
with diabetes are two to four times as likely to develop
cardiovascular disease [2]. The past two decades have
witnessed the introduction of a number of therapies that
are highly effective in the primary and secondary pre-
vention of cardiovascular disease. There is robust evi-
dence that treatment of hypertension and lipids have
cardioprotective benefits independent of their respective
blood pressure and lipid-lowering effects [3-7].* Correspondence: sbutalia@ucalgary.ca
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unless otherwise stated.There is some suggestion that there is differential uti-
lization of preventative (both primary and secondary) ther-
apies between women and men with diabetes. Several
observational studies have documented that women with
diabetes have a higher risk factor burden relative to men,
and others have demonstrated that women are less likely
to achieve recommended targets for blood pressure, chol-
esterol and glucose than men [8-10]. There are small scale
observational studies that do provide some evidence that
women with diabetes are less likely to be treated with car-
dioprotective medications and are less likely to be treated
to established therapeutic targets [9,10]. However, it is not
known if this finding of under-treatment is true at a popu-
lation level which is important given the broader implica-
tions of such findings. The objective of the present study
was to use a large population-level administrative-health
database from a universal-payer environment to compare
the use of evidence-based cardioprotective medications
among women and men with diabetes.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data source and study population
This study was conducted using linked administrative
data from Saskatchewan Health, including the subject,
hospital discharge, physician visits, medical services, drug
and mortality files. Approximately 90% of the Saskatchewan
Health beneficiaries are eligible for prescription drug
coverage. Excluded from eligibility are First Nations People
and some military veterans because their prescription
drugs are covered under federal programs. Persons with
incomplete data or with potentially identifiable data were
removed by Saskatchewan Health data administrators prior
to the conduct of this work. Saskatchewan residents were
eligible for inclusion if they were registered beneficiaries of
Saskatchewan Health, eligible for prescription drug bene-
fits, aged 30 years or older on the index date (date of first
claim for an oral antidiabetic drug), and had continuous
coverage in the provincial health plan for at least three
years before the index date. Among all individuals regis-
tered with Saskatchewan health services, we identified per-
sons with new onset diabetes defined as those who had a
new oral antidiabetic prescription between January 1, 1995
and December 31, 2005. “New” prescription was defined as
no antidiabetic (insulin or oral agent) therapy exposure in
the year prior to the first prescription for an oral antidia-
betic therapy between 1995 and 2005. Oral antidiabetic
therapies are typically dispensed in 100-day supplies once
a patient is in the maintenance stage, so to be eligible, sub-
jects could have no prescriptions for antidiabetic therapies
in 465 days prior to the “new” prescription. Persons with
diabetes were identified by their use of antidiabetic therapy,
a valid method when using comprehensive pharmacy data-
bases [11,12]. We excluded women using metformin alone
if they had a diagnosis for polycystic ovary syndrome, and
all patients with less than three years of coverage prior to
the index date. All included patients were followed until
December 31, 2006.
Outcome and exposure variables
The outcome of interest was utilization of statins,
angiotensin-converting-enzyme inhibitors (ACEi), and
angiotensin receptor blockers (ARB). For the purposes of
this study, utilization was defined as at least one dispensa-
tion for a drug in the 365 days following diabetes diagno-
sis. Because ACEi and ARB have similar cardioprotective
effects, we also included a variable ‘ACEi or ARB’.
Our primary exposure was sex, with the analysis was
stratified by age and cardiovascular disease status. Clinical
practice guidelines for the care of patients with diabetes
currently recommend that all patients over the age of 40
years should receive treatment with a statin, and all pa-
tients over the age of 55 years should receive treatment
with and ACE or ARB [13]. A priori, we expected that pa-
tients above the age of 55 with a history of cardiovasculardisease should be treated with cardioprotective medica-
tions, irrespective of sex. Patients were considered to have
cardiovascular disease at baseline if there was a claim for
at least one of the following in the three years prior to
index date: physician office visit or hospitalization with a
diagnostic code for ischemic heart disease, cardiac dys-
rhythmias, heart failure, cerebrovascular disease or periph-
eral vascular disease using the International Statistical
Classification of Diseases and Related Health Problems,
Ninth and Tenth Revisions; a procedure code for percu-
taneous coronary intervention or coronary artery bypass
grafting surgery; or a prescription for a nitrate or pentoxy-
phylline (Additional file 1: Appendix 1).
Statistical analysis
Baseline characteristics were compared using t-tests for
continuous variables and Chi-square tests for categorical
variables after assuring that assumptions of each test were
met. In order to address the issue of informative cen-
soring, competing risks regression based on the method
described by Fine and Gray, with death treated as a com-
peting event, was used to calculate crude and adjusted
sub-hazard ratios for time-to-first dispensation for women
relative to men [14]. Adjustment variables included age at
diabetes diagnosis, cardiovascular disease status, Chronic
Disease Score (quartile), renal disease, dialysis, physician
office visits (quartile), hospitalizations, days in hospital,
day surgeries (all) in the 3 years prior to diabetes diagno-
sis, year of diabetes diagnosis and pre-existing prescription
for the same medication at baseline [15]. The Chronic
Disease Score is a measure of co-morbidity based on
pharmacy data [15]. Death and discontinuation of health
services coverage (departure from the province) were
considered to be competing risks when they occurred
prior to a dispensation. All analyses were performed using
STATA software Version 11 (StataCorp LP, College Station,
Texas). The study is reported according to STROBE guide-
lines (Additional file 1: Appendix 2) [16].
Ethics approval
This project received ethics approval from the Conjoint
Health Ethics Review Board of the University of Calgary.
Results
After exclusion of participants with fewer than three
years of continuous coverage in the provincial health
plan prior to the index date (n = 758) and those with a
record of insulin dispensation in the three years prior to
index date (n = 157), there were 15,120 (45.4%) women
and 18, 174 (54.6%) men in the study cohort (Table 1).
The mean age of women at the time of diagnosis was
nominally higher than that of men (62.9 ± 15.2 versus
61.7 ± 13.2 years, p <0.001) and women had less cardio-
vascular disease at time of diabetes diagnosis (33.1
Table 1 Characteristics of the study cohort
Men Women p-value
N = 18,174 N = 15,120
(54.6%) (45.4%)
Demographic characteristics
Mean age at DM diagnosis (SD) 61.7 (13.2) 62.9 (15.2) <0.001
Mean age at DM diagnosis (SD) By age group
<55 46.4 (5.9) 44.8 (6.9) <0.001
55+ 68.8 (9.0) 71.1 (9.8) <0.001
Age group <55 years 5,766 (31.6) 4,745 (31.2) 0.457
Mean years of follow-up (SD) 5.10 (3.1) 5.14 (3.1) 0.257
Range of follow up in years 0-12.0 0-12.0
Comorbidity
CDS score (Quartile) <0.001
2 5,258 (28.9) 3,143 (20.8)
3-5 5,161 (28.4) 4,657 (30.8)
6-8 5,004 (27.5) 4,469 (29.6)
9+ 2,751 (15.1) 2,851 (18.9)
Cardiovascular disease status at baseline (diabetes diagnosis) 6,504 (35.8) 5,008 (33.1) <0.0001
Renal disease in the 3 years prior to index 360 (2.0) 247 (1.6) 0.031
Access to care in the 3 years prior to index
Total physician office visits <0.001
0-11 office visits 5,792 (31.9) 2,857 (18.9)
12-21 office visits 4,814 (26.5) 3,579 (23.7)
22-35 office visits 3,976 (21.9) 4,179 (27.6)
36 or more office visits 3,592 (19.8) 4,505 (29.8)
Hospitalizations <0.001
0 11,989 (66.0) 9,661 (63.9)
1 or more 6,185 (34.0) 5,459 (36.1)
Day surgeries <0.001
0 13,146 (72.3) 10,587 (70.0)
1 or more 5,028 (27.7) 4,533 (30.0)
Cardioprotective medication use in the 1 year prior to DM diagnosis
Statin 2,530 (13.9) 2,050 (13.6) 0.339
ACEi 4,576 (25.2) 3,831 (25.3) 0.740
ARB 1,187 (6.5) 1,401 (9.3) <0.0001
ACEi or ARB 5,505 (30.3) 4,977 (32.9) <0.0001
Any of the above 6,541 (36.0) 5,868 (38.8) <0.0001
Abbreviations: DM diabetes mellitus, SD standard deviation, ACEi angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers.
Butalia et al. Diabetology & Metabolic Syndrome 2014, 6:117 Page 3 of 7
http://www.dmsjournal.com/content/6/1/117versus 35.8%, p < 0.0001). More men than women had a
Chronic Disease Score of ≤2 (28.9% versus 20.8%, p <
0.001). Women and men differed in terms of their use of
health services. Women appear to have a greater num-
ber of physician office visits, hospitalizations, and day
surgeries compared to men (p < 0.001 for all compari-
sons; Table 1). The use of any cardioprotective medica-
tion use in the year prior to diabetes diagnosis wasgreater in women compared to men (38.8 versus 36.0%,
p <0.0001; Table 1).
Following the diagnosis of diabetes, overall cardiopro-
tective medication use was low for women and men
(Table 2). Fewer women had a statin (21.4 versus 24.0%,
p < 0.0001) or ACEi (35.4 versus 39.1%, p < 0.0001) dispen-
sation relative to men whereas women had more ARB
(13.3 versus 10.3%, p < 0.0001) dispensations. Overall use
Table 2 Cardioprotective medication use within 1 year of diabetes diagnosis
Men Women p-value
N = 18,174 (54.6) N = 15,120 (45.4)
Statin 4,368 (24.0) 3,232 (21.4) <0.0001
ACEi 7,103 (39.1) 5,351 (35.4) <0.0001
ARB 1875 (10.3) 2,004 (13.3) <0.0001
ACEi or ARB 8,455 (46.5) 6,872 (45.5) 0.05
At least one of the above 9,846 (54.2) 8,011 (53.0) 0.03
Abbreviations: ACEi angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers.
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(53.0 versus 54.2%, p =0.03; Table 2). Upon stratification
by age and cardiovascular disease status, lower proportions
of women below the age of 55 had filled a prescription for
a statin or ACEi and were less likely to receive any cardio-
protective medication than men, irrespective of cardiovas-
cular disease status. For those 55 years and older, once
again a lower proportion of women with cardiovascular
disease had filled a prescription for a statin or ACEi com-
pared to men. In contrast, for older patients without car-
diovascular disease, women were more likely to be using a
statin or an ARB relative to men, and were more likely to
be using any cardioprotective medication (Table 3).
In the year following a diabetes diagnosis, women rela-
tive to men were less likely to use a statin [adjusted sub-
hazard ratio (aSHR) 0.90, 95% CI 0.85 to 0.96], ACEi
(aSHR 0.90, 95% CI 0.86 to 0.94), or any cardioprotective
medication (aSHR 0.93, 95% CI 0.90 to 0.97; Table 4).Table 3 Cardioprotective medication prescription within 1 ye
disease status
< 55 YE
CVD (N = 1,493 )
Men Women
N = 905 N = 588
Statin 366 (40.4) 180 (30.6)
ACEi 431 (47.6) 225 (38.3)
ARB 105 (11.6) 78(13.3)
ACEi or ARB 511 (56.5) 273 (46.4)
At least one of the above 605 (66.9) 340 (57.8)
55 YEA
CVD (N = 10,019)
Men Women
N = 5,599 N = 4,420
Statin 1,680 (30.0) 1,142 (25.8)
ACEi 2,653 (47.4) 1,931 (43.7)
ARB 600 (10.7) 709 (16.0)
ACEi or ARB 3,084 (55.1) 2,458 (55.6)
At least one of the above 3545 (63.3) 2800 (63.4)
Abbreviations: CVD cardiovascular disease, ACEi angiotensin-converting-enzyme inhiConclusions
The results presented herein suggest that the overall use
of cardiovascular medications in patients with diabetes
was less than optimal. Furthermore, our analysis demon-
strates that women are 10% less likely to use a statin or
ACEi and are 7% less likely to use any cardioprotective
medication than men after adjusting for several clinical
differences that might influence the crude assessment of
use. These findings lend support to the hypothesis that
women with diabetes may have a greater risk, not only
because of a greater risk factor burden, but also because
they have less treatment of these risk factors. We ac-
knowledge that the relative differences in use among
women and men were small to moderate; however the
implications of these differences on a population level
could be considerable.
The finding of underuse of therapies that prevent car-
diovascular disease is not novel. The recent Prospectivear of diabetes diagnosis, by sex and cardiovascular
ARS
No CVD (n = 8,953)
p-value Men Women p-value
N = 4,836 N = 4,117
0.0001 997 (20.6) 596 (14.48) <0.0001
0.0004 1,613 (33.4) 1,071 (26.0) <0.0001
0.338 410 (8.5) 402 (9.8) 0.035
0.0001 1,903 (39.4) 1,382 (33.6) <0.0001
0.0004 2281 (47.2) 1608 (39.1) <0.0001
RS +
No CVD (N = 12,829 )
p-value Men Women p-value
N = 6,834 N = 5,995
<0.0001 1,325 (19.4) 1,314 (21.9) 0.0004
0.0002 2,406 (35.2) 2,124 (35.4) 0.8
<0.0001 760 (11.1) 815 (13.6) <0.0001
0.6 2,957 (43.3) 2,759 (46.0) 0.002
0.9 3415 (49.9) 3263 (54.4) <0.0001
bitors, ARB angiotensin receptor blockers.
Table 4 Sub-hazard ratio of statin, ACEi, ARB, ACEi or
ARB, or any cardioprotective medication use in the 1
year following a diabetes diagnosis for women relative to
men
N = 33,294 Crude SHR (95% CI) Adjusted* SHR (95% CI)
Statin 0.90 (0.86 – 0.95) 0.90 (0.85 – 0.96)
ACEi 0.91 (0.87 – 0.95) 0.90 (0.86 – 0.94)
ARB 1.34 (1.24 – 1.43) 1.08 (0.99 – 1.17)
ACEi or ARB 1.00 (0.97 – 1.04) 0.93 (0.89 – 0.97)
Any of the above 1.00 (0.97 – 1.04) 0.93 (0.90 – 0.97)
*Adjusted for age at diabetes diagnosis, cardiovascular disease status, Chronic
Disease Score, renal disease, dialysis, physician office visits, hospitalizations, days
in hospital, day surgeries (all )in the 3 years prior to diabetes diagnosis, year of
diabetes diagnosis and pre-existing prescription for the same medication
at baseline.
Abbreviations: ACEi angiotensin-converting-enzyme inhibitors, ARB angiotensin
receptor blockers, SHR sub-hazard ratio.
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luated the use of drugs for secondary prevention of
cardiovascular disease and found that use was low
worldwide, with the lowest rates in low-income coun-
tries and rural areas [17]. Low cardioprotective medica-
tion use was also observed in high-income countries
[17]. The socio-economic gradient in medication use
documented in PURE suggests that reduced access to
these therapies may be a barrier to their use. In Canada,
observational studies have found similar medication
underuse [18]. However, it is likely that the absolute
levels of use have gone up, partly due to new clinical
trial information and the aging population [18]. The
relative difference in cardiovascular medication use be-
tween women and men, on the other hand, is less likely
to have changed, and may be indicative of an ongoing
sex/gender gap in care.
We also documented sex differences in cardioprotec-
tive medication use by age. This may not be a treatment
inequity per se, as many of these differences may reflect
appropriate risk stratification of individual patients and
clinical judgement of treating physicians. Even though
clinical practice guidelines do recommend that by age 55
all patients should be receiving statins, ACEs or ARBs,
these guidelines are not sex-specific and are based on
evidence from clinical trials that included largely men.
Age and sex are both significant predictors of cardiovas-
cular disease risk in all commonly used cardiovascular
disease risk predication models, and women under the
age of 55 will consistently have a lower predicted risk
compared to men of similar age and risk factor profile.
For example, using the UKPDS risk engine, a 55 year old
female non-smoker with a systolic blood pressure of 140
mmHg and a total:HDL ratio of 4 will have a 10 year risk
for cardiovascular disease of 10.9% [19]. A man with a
similar risk factor profile will have a 10 year risk that is
nearly double at 19.7%. We did not have the ability todo formal risk calculations due to the absence of clinical
information such as systolic blood pressure and choles-
terol levels; however, we were able to control for may
clinical differences including duration of diabetes, sever-
ity of disease and co-morbid disease burden and still
noted that there was a significant sex difference in cardi-
oprotective medication use. Further, while differences in
sex-related risk for cardiovascular disease may account
for differences in medication use among those without
established cardiovascular disease, this cannot explain
the consistent finding of lower use of statins and ACEi
among women with heart disease.
The decision to initiate the medications assessed in
this study is admittedly more complex in women of re-
productive age. These medications are all presently con-
traindicated in pregnant or nursing women. Should a
young woman be eligible for cardioprotective therapy,
either due to a high calculated risk or the presence of
renal or cardiovascular disease, counselling regarding
the potential teratogenicity of these medications and the
need for contraception and family planning must occur.
This of course should not deter the use of these therap-
ies in younger women, but does make clinical decision
making for the physician and patient more complicated.
Other reasons for overall underuse of cardioprotective
medications may be fear of side effects from medica-
tions, concerns of drug-drug interactions, inconvenience
of laboratory surveillance, indirect costs of physician
visits and prescription refills, and/or patient or physician
inertia.
Our study has limitations. As it is an observational study
relying on administrative data, we were limited by the data
elements collected. Most importantly, we do not have clin-
ical information such as control of glycemia, blood pressure
or lipid, which may be associated with differences in medi-
cation use observed among women and men. We could at
least partially address this concern by using multivariable
analyses that control for severity of illness covariates de-
fined from administrative data using validated methodolo-
gies. Ill individuals would likely be visiting their physician
more frequently, may be hospitalized more and may have a
higher Chronic Disease Score. We were unable to identify
patients with co-morbid hypertension or nephropathy (sub-
populations that would have a strong indication for the use
for ACE/ARB +/− statins) in this dataset. While there are
valid administrative data definitions for these conditions,
the data we received had aggregated comorbidity data so
we were unable to isolates specific comorbidities and were
unable to calculate other commonly used co-morbidity in-
dexes like the Charlson Comorbidity Index. We assessed
medication utilization by dispensation, not actual pres-
criptions. Whether the difference in medication use is due
to differences in physician factors (physicians under-
estimating women’s cardiovascular disease risk such that
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factors (patients provided a prescription that is subse-
quently not filled, tolerated, or adhered to) is unclear. Also,
diabetes diagnosis was based on new use of antidiabetic
agents. While this is an accepted method of identifying pa-
tients in pharmacy datasets, it is likely that some patients
with diabetes were missed if they were managed with diet
only. Further, this “new user” methodology is primarily used
to define cohorts based on exposure to specific therapeutic
agents and the validity of therapy use as a proxy for disease
state is less established. Finally, we acknowledge that during
the period of observation, the evidence for the use of sta-
tins, ACEi and ARBs was evolving and guidelines regarding
their use have changed significantly over time. For much of
the observation period, there were no age-specific guide-
lines directing use of these medications [20,21]. More re-
cent evidence would suggest that absolute use overall has
increased [18]. The modest overall use found in our study
may in part be due to appropriate low use early in the ob-
servation period when the benefits of these medications
were less established or these medications were not avail-
able for use; however, we were more interested in assessing
relative use in women compared to men and the relative
difference in cardiovascular medication use between men
and women identified herein is less likely to have changed
over time. We did, nonetheless, conduct a sensitivity ana-
lysis controlling for year of entry into the cohort and our
estimates regarding predictors of use and the sub-hazard
ratio for use by sex or age did not change.
Our study documented significant underuse in effect-
ive cardioprotective medications in women and men
with diabetes both in primary prevention and secondary
prevention. Furthermore, our study documented a pos-
sible care gap in the use of cardioprotective medications
in patients with diabetes, with women less likely to be
treated. Significant opportunity exists to enhance cardio-
protective medication use in women and men with dia-
betes, and efforts should be applied systemically to
improve the quality of care. Future study should also be
directed at assessing the clinical impact of sex differ-
ences in medication use, particularly on cardiovascular
events and mortality.
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